Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders

Journal of Infection

Volumn 60, Issue 4, 2010, Pages 264-270

  Lin, Chaoshuang ^a   Zhu, Jianyun ^a   Zheng, Yubao ^a   Chen, Youming ^a   Wu, Zhebin ^a   Chong, Yutian ^a   Gao, Zhiliang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

GM CSF; Hepatitis B vaccine; Immunization; Non responder

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEOMETRY; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNITY; INJECTION SITE ALLERGY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; LEUKOCYTE COUNT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VACCINATION; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 77952566837     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.01.011     Document Type: Article

References (40)

1. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995, 13:S47-S49.
2. Otag F. False positive HBsAg result in blood donors due to administration of three different recombinant DNA hepatitis B vaccines. Vaccine 2003, 21:3734-3737.
3. Elkayam O., Yaron M., Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002, 61:623-625.
4. Sabidó M., Gavaldà L., Olona N., Ramon J.M. Timing of hepatitis B vaccination: its effect on vaccine response in health care workers. Vaccine 2007, 25:7568-7572.
5. Gandhoke I., Gupta S., Lal S., Khare S. Immune response to recombinant hepatitis B vaccination in adults. J Commun Dis 2003, 35:249-255.
6. Hilleman M.R. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocellular carcinoma caused by hepatitis B virus. Vaccine 2003, 21:4626-4649.
7. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., Margolis H. Immunogenicity of hepatitis B vaccine. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998, 15:1-8.
8. Idilman R., De M.N., Colantoni A., Nadir A., Van Thiel D.H. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002 Feb, 97(2):435-439.
9. Wiedmann M., Liebert U.G., Oesen U., Porst H., Wiese M., Schroeder S., et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000, 31:230-234.
10. Cruciani M., Mengoli C., Serpelloni G., Lanza A., Gomma M., Nardi S., et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009, 27(1):17-22.
11. Liehl E., Hildebrandt J., Lam C., Mayer P. Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results. Eur J Clin Microbiol Infect Dis 1994, 13(Suppl. 2):S9-S17.
12. Tarr P.E., Lin R., Mueller E.A., Kovarik J.M., Guillaume M., Jones T.C. Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 1996, 14:1199-1204.
13. Kim M.J., Nafziger A.N., Harro C.D., Keyserling H.L., Ramsey K.M., Drusano G.L., et al. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 2003, 21:1174-1179.
14. Belloni C., Pistorio A., Tinelli C., Komakec J., Chirico G., Rovelli D., et al. Early immunisation with hepatitis B vaccine: a five year study. Vaccine 2000, 18:1307-1311.
15. Hussain Z., Ali S.S., Husain S.A., Raish M., Sharma D.R., Kar P. Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India. World J Gastroenterol 2005, 11:7165-7168.
16. Oguz Y., Doganci L., Vural A. Seroconversion rates of two different doses of hepatitis B vaccine in Turkish haemodialysis patients. Cent Eur J Public Health 2001, 9:44-45.
17. Estévez Z.C., Betancourt A.A., Muzio González V., Baile N.F., Silva C.V., Bernal F.H., et al. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. Biologicals 2007, 35:115-122.
18. Yucesoy B., Sleijffers A., Kashon M., Garssen J., De Gruijl F.R., Boland G.J., et al. IL-1beta gene polymorphisms influence hepatitis B vaccination. Vaccine 2002, 20:3193-3196.
19. Sleijffers A., Yucesoy B., Kashon M., Garssen J., De Gruijl F.R., Boland G.J., et al. Cytokine polymorphisms play a role in susceptibility to ultraviolet B-induced modulation of immune responses after hepatitis B vaccination. J Immunol 2003, 170:3423-3428.
20. Goldwater P.N. Randomized, comparative trial of 20micrograms vs 40micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997, 15:353-356.
21. Gold Y., Somech R., Mandel D., Peled Y., Reif S. Decreased immuneresponse to hepatitis B eight years after routine vaccination in Israel. Acta Paediatr 2003, 92:1158-1162.
22. Wu J.S., Hwang L.Y., Goodman K.J., Beasley R.P. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 1999, 179:1319-1325.
23. Floreani A., Baldo V., Cristofoletti M., Renzulli G., Valeri A., Zanetti C., et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004, 22:607-610.
24. Anandh U., Bastani B., Ballal S. Granulocyte-macrophage colony stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am J Nephrol 2000, 20:53-56.
25. Evans T.G., Schiff M., Graves B., Agosti J., Barritt M.L., Garner D., et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin Nephrol 2000, 54:138-142.
26. Hess G., Kreiter F., Kosters W., Deusch K. The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. J Viral Hepat 1996, 3:149-153.
27. Singh N.P., Mandal S.K., Thakur A., Kapoor D., Anuradha S., Prakash A., et al. Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure - results of a prospective, randomized trial. Ren Fail 2003, 25:255-266.
28. Kapoor D., Aggarwal S.R., Singh N.P., Thakur V., Sarin S.K. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat 1999, 6:405-409.
29. Hasan M.S., Agosti J.M., Reynolds K.K., Tanzman E., Treanor J.J., Evans T.G. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. J Infect Dis 1999, 180:2023-2026.
30. Sasaki M.G., Foccacia R., de Messias-Reason I.J. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003, 21(31):4545-4549.
31. Kirkpatrick C.H., Wilson W.E.C., Talmage D.W. Immunologic studies in human organ transplantation. I. Observation and characterisation of suppressed cutaneous reactivity in uraemia. J Exp Med 1964, 6:727-742.
32. Raska K., Raskova J., Shea S.M., Frankel R.M., Wood R.H., Lifter J., et al. T-cell subsets and cellular immunity in end-stage renal disease. Am J Med 1983, 6:734-740.
33. Meur S.C., Haver M., Kurz P., Meyer zum Buschenfeld E.K.H., Kohler H. Selective blockade of the antigen receptor mediated pathway of T cell activation in patients with impaired immune responses. J Clin Invest 1987, 6:743-749.
34. Dumann H.D., Meuer S., Meyer zum Buschenfelde E.K.H., Kohler H. Hepatitis B vaccination and interleukin-2 receptor expression in chronic renal failure. Kidney Int 1990, 6:1164-1168.
35. Gibbons R.A.S., Martinez O.M., Garovoy M.R. Altered monocyte function in uraemia. Clin Immunol Immunopathol 1990, 6:66-80.
36. Lieschke G.J., Burgess A.W. Granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor. N Engl J Med 1992, 6:28-35.
37. Jones T., Stern A., Lin R. Potential role of granulocyte-macrophage colony stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis 1994, 6:47-53.
38. Larsen C.P., Ritchie S.C., Hendrix R., Linsley P.S., Hathcock K.S., Hodes R.J., et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 1994, 152:5208-5219.
39. Markowicz S., Engleman E.G. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990, 85:955-961.
40. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-296.